Biogen submits MS drug candidate Plegridy for FDA approval

05/22/2013 | American City Business Journals

Biogen Idec has filed a biologics license application with the FDA for approval to use its interferon-based drug Plegridy as a treatment for relapsing forms of multiple sclerosis. The application was based on data from a late-stage trial indicating that Plegridy significantly reduced disease activity. Biogen also plans a European application within weeks.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI